Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
As expenditure on drug development increases exponentially, the overall drug discovery process requires a sustainable revolution. Since artificial intelligence (AI) is leading the fourth industrial revolution, AI can be considered as a viable solution for unstable drug research and development. Generally, AI is applied to fields with sufficient data such as computer vision and natural language processing, but there are many efforts to revolutionize the existing drug discovery process by applying AI. This review provides a comprehensive, organized summary of the recent research trends in AI-guided drug discovery process including target identification, hit identification, ADMET prediction, lead optimization, and drug repositioning. The main data sources in each field are also summarized in this review. In addition, an in-depth analysis of the remaining challenges and limitations will be provided, and proposals for promising future directions in each of the aforementioned areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding
Devlin, J., Chang, M.-W., Lee, K., & Toutanova, K. (2018) · arXiv · doi:10.48550/arxiv.1810.04805 · Cited by 73,173
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 3×
“…that collects miRNA-disease associations based on experimental evidence from PubMed papers 35 K miRNA-disease associations from 19 K papers STRING [38] A database of physical and functional protein-protein interactions Total 3.1 B protein interactions Therapeutic Target Database (TTD) [39] A…”
BackgroundMethodInfluentialKEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
PubChem Substance and Compound databases
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv951 · Cited by 5,436
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867 · cited 1×
“COSMIC provides somatic mutations in human cancer, which can describe cancer-specific disease characteristics [302].”
BackgroundHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Cited by
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Deng, L.-J., Deng, W.-Q., Fan, S.-R., Chen, M.-F., Qi, M., Lyu, W.-Y., Qi, Q., Tiwari, A. K., Chen, J.-X., Zhang, D.-M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01510-2 · Cited by 366
Dhakal, A., McKay, C., Tanner, J. J., & Cheng, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab476 · Cited by 256
Singh, S., Kumar, R., Payra, S., & Singh, S. K. (2023) · Cureus · doi:10.7759/cureus.44359 · Cited by 154
The machine learning life cycle and the cloud: implications for drug discovery
Spjuth, O., Frid, J., & Hellander, A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1932812 · Cited by 67
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Metadata
- Authors
- Kim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H.
- Venue
- Biotechnology and Bioprocess Engineering
- Published
- 2020-12
- Volume
- 25
- Issue
- 6
- Pages
- 895-930
- ISSN
- 1226-8372 (ISSN-L)
- 1976-3816
- OpenAlex
- W3120486112
- Cited by
- 131
- References
- 61
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches. https://app.cochat.ai/papers/10.1007/s12257-020-0049-y
- The paper
- Kim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H. (2020). Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches. Biotechnology and Bioprocess Engineering. https://doi.org/10.1007/s12257-020-0049-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.